Loading...
Veritas Farms, Inc.
VFRM•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$0.00
$-0.00(-0.00%)

Financial performance has remained strong, with revenue growing from $115059.00 in Q4 2022 to $235941.00 in Q3 2023. Gross profit continued to perform well, with margins at 22% in the latest quarter. Operating income reached -$839737.00 in Q3 2023, holding a steady -356% margin. While R&D and SG&A expenses fluctuated, EBITDA remained robust at -$732903.00. Net income rose to -$1.13M, keeping EPS at -$0.01. With disciplined cost control and operational efficiency, the company supported consistent profitability, reflecting its ability to deliver stable shareholder value.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan